Arfolitixorin
Phase 3Small molecule
Arfolitixorin is one of 37 small molecule programs targeting Colorectal Cancer. It is currently in Phase 3.
2
Indications
3
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
949 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Arfolitixorin
IIsofol Medical AB
Phase 3
Eylea
RegeneronPreclinical
Ketalar
AAultman Health Foundation
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Vascepa
AAmarin Pharma Inc.
Preclinical
Andriol
AAuxilium
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Colorectal Cancer1 trial
Liver Metastases1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Arfolitixorin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- IIsofol Medical AB